<?xml version="1.0" encoding="UTF-8"?>
<p id="Par65">In conclusion, DCP-001 vaccination in elderly AML patients is safe, feasible and leads to the induction or boosting of multifunctional antitumor immunity. In patients with CR and stable peripheral T cell rate-prolonged overall survival was observed (median 36 months). These promising data warrant further testing of this allogeneic off-the-shelf DC vaccine in AML patients in post-chemotherapy complete remission either as monotherapy or in combination with hypomethylating agents or immune checkpoint inhibitors.</p>
